Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)
Author(s) -
Sébastien Gallien,
Valérie Journot,
Willy Rozenbaum,
P. Yéni,
Philippe Morlat,
Isabelle PoizotMartin,
Jacques Reynes,
Véronique Reliquet,
P. Leclercq,
François Simon,
Geneviève Chêne,
JeanMichel Molina,
Corinne Rancinan,
Fabrice Collin,
F Ferchal,
Laurence MorandJoubert,
Pierre Palmer,
A. Charrois,
Isabelle Madelaine,
D. Séréni,
J. L. Vildé,
É. Rosenthal,
François Raffi
Publication year - 2010
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkq395
Subject(s) - didanosine , efavirenz , emtricitabine , medicine , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , viral load
once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom